Insomnia affects about one-third of adults at some point, with roughly 10% experiencing chronic sleep difficulty. Current treatment includes cognitive behavioral therapy for insomnia (CBT-I), which is considered first-line, plus medications like zolpidem and eszopiclone that help with sleep onset or maintenance but carry dependency risks.
What's actually going on in research
Trials are testing dual orexin receptor antagonists that block wake-promoting signals, drugs targeting circadian rhythm misalignment, and digital CBT-I platforms. Researchers are studying insomnia's links to Alzheimer's disease and metabolic health, and testing treatments for people whose insomnia doesn't respond to standard approaches.
Orexin receptor antagonists
Drugs like suvorexant and lemborexant block orexin, a brain chemical that keeps you awake. They may cause less next-day grogginess and lower dependency risk than older sleep medications.
Digital CBT-I
App-based and web-based versions of cognitive behavioral therapy for insomnia are being tested to expand access. Some trials compare digital programs to in-person therapy.
Circadian rhythm treatments
Studies are testing medications and light therapy for people whose internal clocks are misaligned with their desired sleep schedule. Some trials focus on shift workers and jet lag recovery.
What to know before you search
Eligibility typically depends on insomnia duration (chronic vs. short-term), severity measured by sleep diaries or questionnaires, whether you have other medical or psychiatric conditions, and current medication use.
What types of trials are currently open
- Medication trials — Testing new sleep medications, often comparing them to placebo or existing drugs like zolpidem. These typically measure how quickly you fall asleep and how long you stay asleep.
- Behavioral therapy trials — Testing digital or in-person CBT-I programs, often comparing different delivery methods or measuring long-term effectiveness.
- Combination trials — Testing whether pairing medication with CBT-I works better than either alone, especially for chronic insomnia.
- Device trials — Testing wearables, light therapy devices, or neurostimulation devices that aim to improve sleep quality or regulate circadian rhythms.
- Comorbidity trials — Studying insomnia treatments in people who also have depression, anxiety, chronic pain, or other conditions that disrupt sleep.
Recently added Insomnia trials
Track how sleep affects your pain sensitivity and muscle recovery
Sleep is a critical determinant of physiological recovery and pain regulation. Growing evidence suggests that sleep disruption directly heightens central and peripheral pain sensitivity to sensory stimuli (e.g., mechanical pressure, thermal stimuli), serving as a significant risk factor for the onset and persistence of musculoskeletal pain. However, the precise mechanisms through which sleep quality regulates bodily sensory sensitivity and influences the onset, progression, and recovery trajectories of acute musculoskeletal pain in the general public remain insufficiently understood. This study aims to investigate the relationship between sleep condition, pain sensitivity, and musculoskeletal pain dynamics in healthy adults from the general population, regardless of their physical activity levels. Utilizing a standardized, safe, and fully reversible exercise-induced muscle soreness (EIMS) protocol as an experimental pain model, this project will continuously evaluate participants' quantitative sensory testing (QST) profiles and sleep parameters. The findings from this study will advance the mechanistic understanding of sleep-mediated pain modulation, providing evidence-based insights to inform future targeted sleep management and pain prevention interventions.
Receive brain stimulation treatment to help reduce pain sensitivity
Insomnia exacerbates pain sensitivity and impairs physiological recovery from acute musculoskeletal pain. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising non-invasive neuromodulation intervention to alleviate pain and modulate central sensory processing. However, whether rTMS can effectively mitigate insomnia-induced pain hyperalgesia and accelerate the recovery trajectory of acute musculoskeletal pain remains unclear, as does the optimal neuroanatomical stimulation target. Building upon an established experimental pain model, this randomized, sham-controlled study aims to evaluate the restorative effects of three distinct rTMS interventions - targeting the left primary motor cortex (L M1), the right dorsolateral prefrontal cortex (R DLPFC), and a sham condition - on individuals experiencing insomnia. Following a standardized eccentric exercise protocol to induce muscle soreness, participants will receive three sessions of the allocated rTMS intervention at 0, 24, and 48 hours post-exercise. Pain sensitivity, recovery dynamics, and quantitative sensory testing (QST) metrics will be continuously monitored across the recovery timeframe. The findings from this trial will clarify the therapeutic efficacy of rTMS in modulating acute pain under insomnia states and identify the target-specific mechanisms of cortical stimulation, offering evidence-based non-invasive interventions for musculoskeletal pain management.
Find Insomnia trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.